Navigation Links
DATATRAK Signs 6 Year Study with New Device Client
Date:10/7/2009

CLEVELAND, Oct. 7 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a new client with the award of a study for evaluating the use of a thoracic stent graft in aneurysm repair. This six year, US-based study will seek to advance the use of minimally invasive surgical techniques for thoracic aortic aneurysms.

"DATATRAK is excited to work with the leading global provider of innovative devices for the treatment of peripheral vascular disease," said Laurence Birch, DATATRAK's Chairman of the Board. "We look forward to a long and prosperous relationship with this new client."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK to Present at 2009 SCDM Annual Conference
2. DATATRAK eClinical(TM) Supports Multifaceted Studies
3. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. DATATRAK International Reports First Quarter Results for 2008
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
8. Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
9. Sosei Assigns AD 923 Assets to Pharmasol
10. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
11. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)...  Getinge, a leading global provider of innovative ... program -- "Color for the Kids!" -- to ... by The Children,s Heart Foundation. Pediatric patients and ... encouraged to download a coloring picture at ... the gallery on the website. For each artwork ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Semper Fi Fund, one of the nation’s highest-rated veteran ... of videos and a compelling documentary that provide unique insights and powerful advice to ... of its ongoing mission. , Each of the videos focuses on a specific issue ...
(Date:9/19/2017)... Delaware (PRWEB) , ... September 19, 2017 , ... Driving ... and Safety Training Company by Training Industry Inc. as part of its mission to ... , Selection to the first annual 2017 Top 20 Health and Safety Training ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out the ... become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 and ... a deadline of September 2018. , As described in this white ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Colleyville, TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® ... it’s the first in the U.S. to incorporate magnesium, a critical property for ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... Director of its Pflugerville- FM 685 facility. , “We are pleased to announce ... location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room ...
Breaking Medicine News(10 mins):